Celgene – Hot or Not

Celgene is a biopharmaceutical company focused on cancer and inflammatory diseases. It has commercial-stage products and a significant research pipeline. It has a market cap of $101.8 billion, a price to earnings ratio of 49.29. Guest Lungile Malinga from Effectus Capital and resident expert Paul Theron from Vestact decide whether is Celgene hot or not

Partner Content

Disruptive digital solutions is rewiring the DNA of Banking

By Kennedy Mubita, Africa Head, SC Ventures. Imagine a bank whose customers can tap on a wearable device to...

The future of banking; digitization and collaboration as growth accelerants

By Kariuki Ngari, CEO & Managing Director, Standard Chartered, Kenya & East Africa COVID-19 has upended the social and...

Star Quality Speaker Line-Up at Africa Tech Festival 2020

Acknowledged as the world’s largest Africa-focused digital infrastructure and emerging tech event, the Africa Tech Festival has always attracted a stellar line-up of critical thinkers, analysts, futurists, keynote and inspirational speakers. 2020 will more than deliver on that reputation, with a stimulating array of visionary industry presenters, raconteurs and even some sporting greats.


Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox